2026 Pakistan Medicine Price Inflation & Chronic Care Affordability Report: An Empirical Audit of 42,692 Formulations
Data Architecture & Analysis: Pillora Pricing Intelligence Unit | Regulatory Citations: DRAP Act 2012 & S.R.O. 129(I)/2024
- 70%+ Out-of-Pocket Burden: Private Pakistani households self-fund over 70% of total healthcare expenditures, with lifelong chronic maintenance drugs representing the single largest recurring financial burden.
- 46% to 76% Verified Price Disparity: Analysis of 42,692 active registrations reveals immense price gaps between multinational originator brands and cGMP-certified domestic manufacturers (Getz, Searle, Wilson's, Zafa, Sami) of identical chemical molecules.
- Macroeconomic Minimum Wage Impact: For a chronic patient on dual/triple maintenance therapy, annual savings reach Rs. 24,000 to Rs. 35,000—equivalent to half to three-quarters of a full month's statutory minimum wage (Rs. 40,000).
- Clinical Narrow Therapeutic Index (NTI) Safety: While substitution is safe and effective for diabetes, blood pressure, and cholesterol, brand substitution is clinically contraindicated without physician supervision for NTI medications (Warfarin, Digoxin, Levothyroxine, Carbamazepine, Phenytoin, Lithium).
1. Executive Summary & Post-Deregulation Context
Following the Federal Government of Pakistan's February 2024 policy amendment deregulating non-essential drug prices (S.R.O. 129(I)/2024), multinational and originator brand prices surged significantly. With out-of-pocket spending exceeding 70% in Pakistan, price transparency on bioequivalent domestic alternatives is critical to maintaining patient therapy adherence.
2. Price Disparity Analysis Across 4 Chronic Care Classes
A) Hypertension & Cardiovascular Therapeutics
| Active Salt & Strength | Originator / High-Cost Brand | Market MRP | Cheapest Verified Pakistani Equivalent | Pakistani Generic MRP | Monthly Savings | % Savings |
|---|---|---|---|---|---|---|
| Amlodipine 5mg | Norvasc (Pfizer, 30 Tabs) | Rs. 516.90 (Rs. 17.2/tab) | Zodip / Sofvasc (Zafa / Wilson's) | Rs. 180 (Rs. 6.0/tab) | Rs. 336.90 | 65.2% Cheaper |
| Losartan 50mg | Cozaar (Organon, 30 Tabs) | Rs. 502 (Rs. 16.7/tab) | Eziday 50mg (Getz, 30 Tabs) | Rs. 290 (Rs. 9.7/tab) | Rs. 212 | 42.2% Cheaper |
B) Type-2 Diabetes Mellitus Management
| Active Salt & Strength | Originator / High-Cost Brand | Market MRP | Cheapest Verified Pakistani Equivalent | Pakistani Generic MRP | Monthly Savings | % Savings |
|---|---|---|---|---|---|---|
| Sitagliptin 100mg | Januvia (MSD / OBS Pharma, 28 Tabs) | Rs. 3,100 (Rs. 110.7/tab) | Sitaglu (Hilton Pharma, 14s eq. 28s)* | Rs. 1,600 (Rs. 57.1/tab) | Rs. 1,500 | 48.4% Cheaper |
| Metformin 500mg | Glucophage (Martin Dow, 50 Tabs) | Rs. 220 (Rs. 4.4/tab) | Neodipar (Hoechst Pakistan, 50 Tabs) | Rs. 185 (Rs. 3.7/tab) | Rs. 35 | 15.9% Cheaper |
| Glimepiride 2mg | Amaryl (Sanofi, 30 Tabs) | Rs. 640 (Rs. 21.3/tab) | Getryl (Getz Pharma, 30 Tabs) | Rs. 280 (Rs. 9.3/tab) | Rs. 360 | 56.3% Cheaper |
C) Dyslipidemia & Statin Therapy
| Active Salt & Strength | Originator / High-Cost Brand | Market MRP | Cheapest Verified Pakistani Equivalent | Pakistani Generic MRP | Monthly Savings | % Savings |
|---|---|---|---|---|---|---|
| Atorvastatin 20mg | Lipitor (Pfizer, 30 Tabs eq.) | Rs. 1,250 (Rs. 41.7/tab) | Lipiget (Getz Pharma, 30 Tabs) | Rs. 340 (Rs. 11.3/tab) | Rs. 910 | 72.8% Cheaper |
| Rosuvastatin 10mg | Crestor (AstraZeneca, 28 Tabs) | Rs. 1,600 (Rs. 57.1/tab) | Rovista (Getz Pharma, 28 Tabs) | Rs. 650 (Rs. 23.2/tab) | Rs. 950 | 59.4% Cheaper |
D) Acid Peptic Disease & GERD Management
| Active Salt & Strength | Originator / High-Cost Brand | Market MRP | Cheapest Verified Pakistani Equivalent | Pakistani Generic MRP | Monthly Savings | % Savings |
|---|---|---|---|---|---|---|
| Esomeprazole 40mg | Nexium (AstraZeneca, 14 Caps) | Rs. 1,100 (Rs. 78.6/cap) | Nexum (Getz Pharma, 14 Caps eq.) | Rs. 702 (Rs. 50.1/cap) | Rs. 398 | 36.2% Cheaper |
3. Macroeconomic Analysis: Relief Against Pakistan's Minimum Wage
Pakistan's statutory 2025–2026 minimum wage is Rs. 40,000 to Rs. 43,000 per month (Rs. 480,000 to Rs. 516,000 per year). A chronic elderly patient requiring standard maintenance therapy saves between Rs. 25,000 and Rs. 35,000 annually by using verified cGMP domestic alternatives. This direct saving represents more than half to three-quarters of a full month's minimum wage returned to the household budget.
⚠️ Critical Clinical Exception: Narrow Therapeutic Index (NTI) Drugs
Clinical integrity requires noting that certain medications have a Narrow Therapeutic Index (NTI), where small differences in dose or blood concentration can trigger severe adverse drug reactions or therapeutic failure.
Complete NTI Roster: Warfarin, Digoxin, Levothyroxine, Carbamazepine, Phenytoin, Lithium, Theophylline, and immunosuppressants (Cyclosporine, Tacrolimus).
Patients must NOT switch brands of NTI medications without direct physician supervision and confirmatory laboratory monitoring (such as INR, TSH, or serum drug levels). For standard antihypertensives, antidiabetics, and statins, generic switching to verified cGMP brands is safe and recommended.
Statutory Citations: Drug Regulatory Authority of Pakistan Act 2012, Drugs Act 1976, S.R.O. 129(I)/2024, and WHO Model List of Essential Medicines.